{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:43:04Z","timestamp":1778694184593,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ijcard.2017.02.046","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T10:45:40Z","timestamp":1487760340000},"page":"107-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering"],"prefix":"10.1016","volume":"236","author":[{"given":"Giampaolo","family":"Niccoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josip An\u0111elo","family":"Borovac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Vetrugno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo G","family":"Camici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2017.02.046_bb0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2005.01.005","article-title":"Physiology and pharmacology of the cardiac pacemaker (\u201cfunny\u201d) current","volume":"107","author":"Baruscotti","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0010","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1007\/s12325-016-0377-7","article-title":"Effectiveness and tolerability of ivabradine with or without concomitant beta-blocker therapy in patients with chronic stable angina in routine clinical practice","volume":"33","author":"Perings","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0015","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000388","article-title":"Role of the funny current inhibitor ivabradine in cardiac pharmacotherapy: a systematic review","author":"Petite","year":"2016","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0020","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"ehw128","author":"Ponikowski","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0025","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0030","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0035","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0040","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0045","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/CIR.0000000000000435","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0050","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40265-016-0567-2","article-title":"Ivabradine: cardioprotection by and beyond heart rate reduction","volume":"76","author":"Heusch","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0055","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1161\/CIRCRESAHA.114.302804","article-title":"Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon","volume":"114","author":"Soukoulis","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/1755-5922.12080","article-title":"Is there a role for ivabradine beyond its conventional use?","volume":"32","author":"Bonadei","year":"2014","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2016.04.001","article-title":"Ivabradine in chronic stable angina: effects by and beyond heart rate reduction","volume":"215","author":"Camici","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/280235a0","article-title":"How does adrenaline accelerate the heart?","volume":"280","author":"Brown","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/351145a0","article-title":"Direct activation of cardiac pacemaker channels by intracellular cyclic AMP","volume":"351","author":"DiFrancesco","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.physiol.63.1.235","article-title":"Molecular diversity of pacemaker ion channels","volume":"63","author":"Kaupp","year":"2001","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0085","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehn337","article-title":"Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction","volume":"29","author":"Heusch","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0090","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrcardio.2016.84","article-title":"Heart rate reduction in coronary artery disease and heart failure","volume":"13","author":"Ferrari","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0095","first-page":"1","article-title":"Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing","volume":"43","author":"Lanza","year":"2006","journal-title":"Adv. Cardiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejim.2015.02.009","article-title":"Heart rate and cardiovascular protection","volume":"26","author":"Caetano","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0105","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.jacc.2010.09.014","article-title":"Vascular pathophysiology in response to increased heart rate","volume":"56","author":"Custodis","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0110","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/sj.bjp.0707673","article-title":"Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents","volume":"153","author":"Heusch","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0115","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","article-title":"Heart rate lowering by specific and selective I f current inhibition with ivabradine","volume":"64","author":"DiFrancesco","year":"2004","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2017.02.046_bb0120","first-page":"157","article-title":"Mechanisms of benefit in the ischemic myocardium due to heart rate reduction","volume":"85","author":"Guth","year":"1990","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0125","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/01.RES.60.5.738","article-title":"Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs","volume":"60","author":"Guth","year":"1987","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0130","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/01.CIR.101.6.689","article-title":"\u03b1-Adrenergic coronary vasoconstriction and myocardial ischemia in humans","volume":"101","author":"Heusch","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0135","doi-asserted-by":"crossref","first-page":"H676","DOI":"10.1152\/ajpheart.00564.2002","article-title":"Contributions of heart rate and contractility to myocardial oxygen balance during exercise","volume":"284","author":"Colin","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0140","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/bjp.2008.347","article-title":"Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction","volume":"155","author":"Heusch","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0145","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijcard.2012.04.076","article-title":"Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: a pilot study","volume":"158","author":"Dominguez-Rodriguez","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0150","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1111\/bph.13220","article-title":"Pleiotropic, heart rate-independent cardioprotection by ivabradine","volume":"172","author":"Kleinbongard","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.atherosclerosis.2010.11.035","article-title":"Ivabradine improves coronary flow reserve in patients with stable coronary artery disease","volume":"215","author":"Skalidis","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0160","first-page":"719","article-title":"Comparison of a beta-blocker and an if current inhibitor in rabbits with myocardial infarction","volume":"47","author":"Langenbach","year":"2006","journal-title":"J. Cardiovasc. Surg."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0165","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/00005344-200311000-00016","article-title":"Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs","volume":"42","author":"Vilaine","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0170","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.yjmcc.2011.02.016","article-title":"The in-situ pig heart with regional ischemia\/reperfusion - ready for translation","volume":"50","author":"Heusch","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0175","doi-asserted-by":"crossref","first-page":"H590","DOI":"10.1152\/ajpheart.00047.2007","article-title":"Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen","volume":"293","author":"Dedkov","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0180","doi-asserted-by":"crossref","first-page":"H322","DOI":"10.1152\/ajpheart.01337.2008","article-title":"Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy","volume":"297","author":"Christensen","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0185","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ar.21081","article-title":"Chronic heart rate reduction facilitates cardiomyocyte survival after myocardial infarction","volume":"293","author":"Zhang","year":"2010","journal-title":"Anat. Rec."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0190","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1074248414553231","article-title":"Effect of chronic heart rate reduction by I(f) current inhibitor ivabradine on left ventricular remodeling and systolic performance in middle-aged rats with postmyocardial infarction heart failure","volume":"20","author":"Dedkov","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0195","doi-asserted-by":"crossref","first-page":"e002989","DOI":"10.1161\/JAHA.115.002989","article-title":"Heart rate reduction with ivabradine protects against left ventricular remodeling by attenuating infarct expansion and preserving remote-zone contractile function and synchrony in a mouse model of reperfused myocardial infarction","volume":"5","author":"O'Connor","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0200","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/eurheartj\/ehp554","article-title":"Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12\/12.6 expression","volume":"31","author":"Couvreur","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0205","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/cvr\/cvp158","article-title":"Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart","volume":"84","author":"Ceconi","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0210","doi-asserted-by":"crossref","first-page":"H366","DOI":"10.1152\/ajpheart.01117.2009","article-title":"Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling","volume":"300","author":"Ceconi","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0215","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1476-5381.2011.01627.x","article-title":"Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression","volume":"165","author":"Suffredini","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0220","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/jcp.24507","article-title":"Ivabradine protects against ventricular arrhythmias in acute myocardial infarction in the rat","volume":"229","author":"Mackiewicz","year":"2014","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0225","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.yjmcc.2013.02.001","article-title":"Selective heart rate reduction with ivabradine slows ischaemia-induced electrophysiological changes and reduces ischaemia-reperfusion-induced ventricular arrhythmias","volume":"59","author":"Ng","year":"2013","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0230","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.resuscitation.2011.03.032","article-title":"Heart rate reduction with ivabradine increases ischaemia-induced ventricular fibrillation threshold: role of myocyte structure and myocardial perfusion","volume":"82","author":"Vaillant","year":"2011","journal-title":"Resuscitation"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0235","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.resuscitation.2012.07.041","article-title":"Ivabradine but not propranolol delays the time to onset of ischaemia-induced ventricular fibrillation by preserving myocardial metabolic energy status","volume":"84","author":"Vaillant","year":"2013","journal-title":"Resuscitation"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0240","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40256-016-0178-z","article-title":"Ivabradine: a review of labeled and off-label uses","volume":"16","author":"Oliphant","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0245","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ajem.2014.01.017","article-title":"Adding ivabradine may reduce elevated heart rate in acute patients when beta blockers are ineffective","volume":"32","author":"Trivi","year":"2014","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0250","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cardfail.2009.05.013","article-title":"Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings","volume":"15","author":"Fasullo","year":"2009","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0255","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/2048872613489305","article-title":"Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study","volume":"2","author":"Steg","year":"2013","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0260","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.acvd.2013.12.001","article-title":"Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: a pilot study","volume":"107","author":"Gerbaud","year":"2014","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0265","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40261-016-0424-9","article-title":"Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective study","volume":"36","author":"Barilla","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0270","first-page":"27","article-title":"Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus","volume":"82","author":"Kondrat'ev","year":"2009","journal-title":"Ter. Arkh."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0275","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2017.02.046_bb0280","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/clc.22578","article-title":"The risk of atrial fibrillation with ivabradine treatment: a meta-analysis with trial sequential analysis of more than 40000 patients","volume":"39","author":"Tanboga","year":"2016","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2017.02.046_bb0285","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4172\/2368-0512.1000056","article-title":"Safety, tolerability and efficacy of ivabradine for control of sinus tachycardia in patients undergoing inotropic therapy","volume":"3","author":"Porcile","year":"2016","journal-title":"Curr Res Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316347775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316347775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T19:59:08Z","timestamp":1568836748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316347775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":57,"alternative-id":["S0167527316347775"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2017.02.046","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2017.02.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}